Alaunos Therapeutics Inc TCRT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.77
- Day Range
- $3.76–3.87
- 52-Week Range
- $3.63–72.75
- Bid/Ask
- $3.76 / $3.81
- Market Cap
- $6.02 Mil
- Volume/Avg
- 8,598 / 10,181
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 66.82
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
- Website
- https://www.alaunos.com
Comparables
Valuation
|
Metric
|
TCRT
|
LYEL
|
ITOS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.26 | 0.69 | 1.14 |
Price/Sales | 66.82 | 6,074.07 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
TCRT
LYEL
ITOS
Financial Strength
|
Metric
|
TCRT
|
LYEL
|
ITOS
|
|---|---|---|---|
Quick Ratio | 3.34 | 16.27 | 12.80 |
Current Ratio | 4.87 | 16.51 | 13.51 |
Interest Coverage | −24.07 | — | — |
Quick Ratio
TCRT
LYEL
ITOS
Profitability
|
Metric
|
TCRT
|
LYEL
|
ITOS
|
|---|---|---|---|
Return on Assets (Normalized) | −85.84% | −21.31% | −16.56% |
Return on Equity (Normalized) | −124.33% | −24.24% | −18.86% |
Return on Invested Capital (Normalized) | −96.60% | −25.73% | −22.78% |
Return on Assets
TCRT
LYEL
ITOS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Vtgpztfd | Qlgnh | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rdtwrcrqj | Yplzzct | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vtcbkkp | Vbfwqkq | $118.7 Bil | |||
| Moderna Inc
MRNA
| Sssxvfkch | Wyx | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Hzmbvbk | Hdxwlh | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Kmsbfqw | Zmxk | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Lzygxywy | Snrhh | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qnwpjkqm | Lrhwrw | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Wtqsrswl | Rfmt | $15.0 Bil | |||
| Incyte Corp
INCY
| Prmyrkcq | Yvpnhr | $13.5 Bil |